Citi Initiates Bullish Coverage on SMid Cap Biotechs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ALNY?
Source: seekingalpha
- Analyst Rating Upgrade: Citi analyst Eric Joseph initiated Buy ratings on five biotech companies including Ionis (IONS), Alnylam (ALNY), and BioMarin (BMRN), reflecting a positive outlook for significant growth in the cardiovascular, metabolism, and endocrine sectors, which indicates strong confidence in the biotech industry.
- Ionis Price Target: The analyst set a $115 price target for Ionis, emphasizing that its pipeline based on antisense oligonucleotides provides a solid foundation for durable growth, showcasing confidence in its future performance.
- BioMarin Valuation Discount: BioMarin received a $75 price target, with analysts noting its EV/Rev ratio of 4x is significantly lower than peers' 8-9x, indicating a substantial valuation discount that may attract investor interest.
- Alnylam Investment Opportunity: Alnylam's price target is set at $380, with analysts arguing that despite its year-to-date underperformance, the impressive market launch of its heart disease therapy Amvuttra presents an attractive buying opportunity, signaling potential for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 286.270
Low
351.00
Averages
479.53
High
580.00
Current: 286.270
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Citi Initiates Bullish Coverage on SMid Cap Biotechs
- Analyst Rating Upgrade: Citi analyst Eric Joseph initiated Buy ratings on five biotech companies including Ionis (IONS), Alnylam (ALNY), and BioMarin (BMRN), reflecting a positive outlook for significant growth in the cardiovascular, metabolism, and endocrine sectors, which indicates strong confidence in the biotech industry.
- Ionis Price Target: The analyst set a $115 price target for Ionis, emphasizing that its pipeline based on antisense oligonucleotides provides a solid foundation for durable growth, showcasing confidence in its future performance.
- BioMarin Valuation Discount: BioMarin received a $75 price target, with analysts noting its EV/Rev ratio of 4x is significantly lower than peers' 8-9x, indicating a substantial valuation discount that may attract investor interest.
- Alnylam Investment Opportunity: Alnylam's price target is set at $380, with analysts arguing that despite its year-to-date underperformance, the impressive market launch of its heart disease therapy Amvuttra presents an attractive buying opportunity, signaling potential for future growth.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $119.78 per share, with a high of $179.64, and a current trading price of $163.87, indicating relative stability in a volatile market that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in better market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETF.
See More
Alnylam's New Therapy Reduces Cardiovascular Event Risks
- Sustained Efficacy: The HELIOS-B study demonstrated that vutrisiran significantly reduced all-cause mortality and cardiovascular events in ATTR-CM patients, particularly in the 65% of patients with atrial fibrillation, highlighting its potential as a first-line treatment option.
- Safety Analysis: A pooled analysis of over 25,000 patient-years indicated that the rates of vitamin A deficiency-related ocular adverse events were low and comparable to placebo, reinforcing confidence in the safety profile of vutrisiran for clinical use.
- Long-Term Study Design: The DemonsTTRate study aims to enroll over 2,000 ATTR-CM patients to generate up to five years of real-world clinical outcome data, further validating the clinical effectiveness and treatment patterns of vutrisiran.
- Global Experience Accumulation: Vutrisiran has accumulated over 13,000 patient-years of global experience in both ATTR-CM and hereditary transthyretin-mediated amyloidosis (hATTR-PN), reflecting its efficacy and safety across diverse patient populations.
See More
Alnylam to Present New Vutrisiran Data at Heart Failure 2026
- New Data Presentation: Alnylam Pharmaceuticals will present new data analyses for vutrisiran at the Heart Failure 2026 congress in Barcelona from May 9-12, 2026, further supporting its efficacy as a first-line treatment for patients with cardiomyopathy.
- Clinical Study Validation: The HELIOS-B study demonstrates vutrisiran's adaptability to patients with high disease burden, indicating its potential value in complex clinical scenarios, which may enhance treatment options for patients.
- Global Observational Study: Alnylam will also introduce the design of the DemonsTTRate study, aimed at evaluating the real-world use of vutrisiran, emphasizing the company's commitment to long-term efficacy and potentially providing critical data for future clinical practices.
- Safety Analysis: The congress will showcase a safety analysis of vutrisiran related to vitamin A, assessing adverse reactions in clinical trials and real-world datasets, ensuring patient safety and treatment effectiveness during administration.
See More
Alnylam Pharmaceuticals Q1 Results Exceed Expectations
- Performance Beat: Alnylam Pharmaceuticals reported Q1 revenue of $1.2 billion, exceeding forecasts by 4.5%, with earnings per share (EPS) at $1.51, 67% above expectations, indicating strong financial performance that boosts investor confidence.
- Future Growth Outlook: Analysts forecast revenues of $5.61 billion in 2026, reflecting a 31% increase from the past 12 months, with EPS expected to soar 86% to $7.51, showcasing a more bullish sentiment towards the company's earnings potential.
- Stable Price Target: Despite the improved earnings outlook, the consensus price target remains unchanged at $449, suggesting that the market does not anticipate significant long-term value creation, prompting investors to consider diverse valuation opinions.
- Industry Growth Comparison: Alnylam is projected to achieve an annualized growth rate of 43% by 2026, significantly outpacing the 21% growth forecast for similar companies, highlighting its competitive advantage and market potential in the biopharmaceutical sector.
See More
Alnylam Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Alnylam reported over $1 billion in global net product revenues for Q1 2026, with TTR revenue reaching $910 million, indicating strong performance in the TTR market and supporting the achievement of the annual sales guidance of $4.4 billion to $4.7 billion.
- Strategic Collaboration Expansion: CEO Yvonne Greenstreet highlighted new partnerships aimed at enhancing TTR disease awareness and diagnosis, reflecting Alnylam's pursuit of global leadership under its 'Alnylam 2030' strategy, which focuses on sustainable innovation for business growth.
- Increased R&D Spending: CFO Jeffrey Poulton reported non-GAAP R&D expenses of $335 million, a 39% increase, indicating ongoing investment in research and development, while maintaining profitability, showcasing confidence in future product development.
- Market Dynamics Analysis: Management emphasized that despite challenges from German pricing adjustments and U.S. insurance reauthorizations, Q1 results were consistent with expectations, demonstrating the company's flexibility and adaptability in navigating market fluctuations.
See More
Citi Initiates Bullish Coverage on SMid Cap Biotechs
- Analyst Rating Upgrade: Citi analyst Eric Joseph initiated Buy ratings on five biotech companies including Ionis (IONS), Alnylam (ALNY), and BioMarin (BMRN), reflecting a positive outlook for significant growth in the cardiovascular, metabolism, and endocrine sectors, which indicates strong confidence in the biotech industry.
- Ionis Price Target: The analyst set a $115 price target for Ionis, emphasizing that its pipeline based on antisense oligonucleotides provides a solid foundation for durable growth, showcasing confidence in its future performance.
- BioMarin Valuation Discount: BioMarin received a $75 price target, with analysts noting its EV/Rev ratio of 4x is significantly lower than peers' 8-9x, indicating a substantial valuation discount that may attract investor interest.
- Alnylam Investment Opportunity: Alnylam's price target is set at $380, with analysts arguing that despite its year-to-date underperformance, the impressive market launch of its heart disease therapy Amvuttra presents an attractive buying opportunity, signaling potential for future growth.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $119.78 per share, with a high of $179.64, and a current trading price of $163.87, indicating relative stability in a volatile market that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in better market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETF.
See More
Alnylam's New Therapy Reduces Cardiovascular Event Risks
- Sustained Efficacy: The HELIOS-B study demonstrated that vutrisiran significantly reduced all-cause mortality and cardiovascular events in ATTR-CM patients, particularly in the 65% of patients with atrial fibrillation, highlighting its potential as a first-line treatment option.
- Safety Analysis: A pooled analysis of over 25,000 patient-years indicated that the rates of vitamin A deficiency-related ocular adverse events were low and comparable to placebo, reinforcing confidence in the safety profile of vutrisiran for clinical use.
- Long-Term Study Design: The DemonsTTRate study aims to enroll over 2,000 ATTR-CM patients to generate up to five years of real-world clinical outcome data, further validating the clinical effectiveness and treatment patterns of vutrisiran.
- Global Experience Accumulation: Vutrisiran has accumulated over 13,000 patient-years of global experience in both ATTR-CM and hereditary transthyretin-mediated amyloidosis (hATTR-PN), reflecting its efficacy and safety across diverse patient populations.
See More
Alnylam to Present New Vutrisiran Data at Heart Failure 2026
- New Data Presentation: Alnylam Pharmaceuticals will present new data analyses for vutrisiran at the Heart Failure 2026 congress in Barcelona from May 9-12, 2026, further supporting its efficacy as a first-line treatment for patients with cardiomyopathy.
- Clinical Study Validation: The HELIOS-B study demonstrates vutrisiran's adaptability to patients with high disease burden, indicating its potential value in complex clinical scenarios, which may enhance treatment options for patients.
- Global Observational Study: Alnylam will also introduce the design of the DemonsTTRate study, aimed at evaluating the real-world use of vutrisiran, emphasizing the company's commitment to long-term efficacy and potentially providing critical data for future clinical practices.
- Safety Analysis: The congress will showcase a safety analysis of vutrisiran related to vitamin A, assessing adverse reactions in clinical trials and real-world datasets, ensuring patient safety and treatment effectiveness during administration.
See More
Alnylam Pharmaceuticals Q1 Results Exceed Expectations
- Performance Beat: Alnylam Pharmaceuticals reported Q1 revenue of $1.2 billion, exceeding forecasts by 4.5%, with earnings per share (EPS) at $1.51, 67% above expectations, indicating strong financial performance that boosts investor confidence.
- Future Growth Outlook: Analysts forecast revenues of $5.61 billion in 2026, reflecting a 31% increase from the past 12 months, with EPS expected to soar 86% to $7.51, showcasing a more bullish sentiment towards the company's earnings potential.
- Stable Price Target: Despite the improved earnings outlook, the consensus price target remains unchanged at $449, suggesting that the market does not anticipate significant long-term value creation, prompting investors to consider diverse valuation opinions.
- Industry Growth Comparison: Alnylam is projected to achieve an annualized growth rate of 43% by 2026, significantly outpacing the 21% growth forecast for similar companies, highlighting its competitive advantage and market potential in the biopharmaceutical sector.
See More
Alnylam Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Alnylam reported over $1 billion in global net product revenues for Q1 2026, with TTR revenue reaching $910 million, indicating strong performance in the TTR market and supporting the achievement of the annual sales guidance of $4.4 billion to $4.7 billion.
- Strategic Collaboration Expansion: CEO Yvonne Greenstreet highlighted new partnerships aimed at enhancing TTR disease awareness and diagnosis, reflecting Alnylam's pursuit of global leadership under its 'Alnylam 2030' strategy, which focuses on sustainable innovation for business growth.
- Increased R&D Spending: CFO Jeffrey Poulton reported non-GAAP R&D expenses of $335 million, a 39% increase, indicating ongoing investment in research and development, while maintaining profitability, showcasing confidence in future product development.
- Market Dynamics Analysis: Management emphasized that despite challenges from German pricing adjustments and U.S. insurance reauthorizations, Q1 results were consistent with expectations, demonstrating the company's flexibility and adaptability in navigating market fluctuations.
See More
